Dennis Powell
American Cyanamid
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dennis Powell.
Bioorganic & Medicinal Chemistry Letters | 2000
Yanong D. Wang; Karen Miller; Diane H. Boschelli; Fei Ye; Biqi Wu; M. Brawner Floyd; Dennis Powell; Allan Wissner; Jennifer Weber; Frank Boschelli
Src is a nonreceptor tyrosine kinase involved in signaling pathways that control proliferation, migration, and angiogenesis. Increased Src expression and activity are associated with an increase in tumor malignancy and poor prognosis. Several quinolines and quinazolines were identified as potent and selective inhibitors of Src kinase activity.
Journal of Medicinal Chemistry | 2009
Edward J. Salaski; Girija Krishnamurthy; Weidong Ding; Ker Yu; Shabana Insaf; Clark N. Eid; Jaechul Shim; Jeremy I. Levin; Keiko Tabei; Lourdes Toral-Barza; Weiguo Zhang; Leonard A. McDonald; Erick Honores; Cilien Hanna; Ayako Yamashita; Bernard D. Johnson; Zhong Li; Leif M. Laakso; Dennis Powell; Tarek S. Mansour
The naturally occurring pyranonaphthoquinone (PNQ) antibiotic lactoquinomycin and related aglycones were found to be selective inhibitors of the serine-threonine kinase AKT. A set of synthetic PNQs were prepared and a minimum active feature set and preliminary SAR were determined. PNQ lactones inhibit the proliferation of human tumor cell lines containing constitutively activated AKT and show expected effects on cellular biomarkers. Biochemical data are presented supporting a proposed bioreductive alkylation mechanism of action.
Bioorganic & Medicinal Chemistry Letters | 2000
Nan Zhang; Biqi Wu; Dennis Powell; Allan Wissner; Middleton Brawner Floyd; Eleonora D. Kovacs; Lourdes Toral-Barza; Constance Kohler
A series of 3-cyano-4-(phenoxyanilino)cyanoquinolines has been prepared as MEK (MAP kinase kinase) inhibitors. The best activity is seen with alkoxy groups at both the 6- and 7-positions. The lead compounds show low nanomolar IC50s against MAP kinase kinase, and have potent inhibitory activity in tumor cells.
Bioorganic & Medicinal Chemistry Letters | 2002
Diane H. Boschelli; Daniel Y. Wang; Fei Ye; Ayako Yamashita; Nan Zhang; Dennis Powell; Jennifer Weber; Frank Boschelli
Based on a screening lead from a yeast-based assay to identify Src family kinase inhibitors, a series of 4-anilino-7-thienyl-3-quinolinecarbonitriles was prepared. When the thiophene ring was substituted with a water-solubilizing group in a 2,5-, 3,5- or 2,4-pattern, potent inhibition of Src kinase activity was observed.
Tetrahedron Letters | 1994
Ryan Holcomb; Steven R. Schow; Semiramis Ayral-Kaloustian; Dennis Powell
Abstract meso -2,6-Diaminopimelic acid, an important linking component of bacterial cell walls and a biosynthetic precursor of l -lysine has been prepared differentially protected in a stereospecific manner from both l -aspartic and l -glutamic acid. The key step to establish the second chiral center involves the asymmetric reduction of a pyruvate moiety with Alpine-Borane®. S -2-Amino-6-oxopimelic acid, the hydrolyzed open chain form of tetrahydrodipicolinic acid, a biosynthetic precursor of meso -2,6-diaminopimelic acid, was also prepared via deprotection of the key pyruvate intermediate.
Bioorganic & Medicinal Chemistry Letters | 2002
Dan M. Berger; Minu Dutia; Dennis Powell; Allan Wissner; Frenel DeMorin; Yuri E. Raifeld; Jennifer Weber; Frank Boschelli
A series of substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles has been prepared as Src kinase inhibitors. Optimal activity is observed with compounds that have basic amines attached via the para position of the 7-phenyl ring, and a hydrogen atom at the C-6 position. The best compounds are low nanomolar inhibitors of Src kinase, and have potent activity against Src-transformed fibroblast cells.
Bioorganic & Medicinal Chemistry Letters | 2001
Nan Zhang; Biqi Wu; Nancy H. Eudy; A. Yanong Wang; Fei Ye; Dennis Powell; Allan Wissner; Larry Feldberg; Steven C. Kim; Robert Mallon; Eleonora D. Kovacs; Lourdes Toral-Barza; Constance Kohler
A series of 4-anilino-3-cyano-6,7-dialkoxyquinolines with different substituents attached to the 4-anilino group has been prepared that are potent MEK (MAP kinase kinase) inhibitors. The best activity is obtained when a phenyl or a thienyl group is attached to the para-position of the aniline through a hydrophobic linker, such as an oxygen, a sulfur, or a methylene group. The most active compounds show low nanomolar IC(50)s against MEK (MAP kinase kinase), and have potent growth inhibitory activity in LoVo cells (human colon tumor line).
Organic Letters | 2009
Xiaolun Wang; Edward J. Salaski; Dan M. Berger; Dennis Powell
It was found that solvent hydrogen bond basicity (SHBB) significantly affects the regiochemistry of the S(N)Ar reaction between secondary amines and activated polyfluoroarenes. A plausible mechanism involving a six-membered transition state is invoked for the formation of an ortho-substituted isomer, which is likely organized by a hydrogen bond. Evidence for this hypothesis is presented, and a regioselective amination reaction of activated polyfluoroarenes has been developed.
Bioorganic & Medicinal Chemistry Letters | 2003
Dan M. Berger; Minu Dutia; Dennis Powell; Biqi Wu; Allan Wissner; Diane H. Boschelli; M. Brawner Floyd; Nan Zhang; Nancy Torres; Jeremy I. Levin; Xuemei Du; Donald Wojciechowicz; Carolyn Discafani; Constance Kohler; Steven C. Kim; Larry Feldberg; Karen Collins; Robert Mallon
4-[3-Chloro-4-(1-methyl-1H-imidazol-2-ylsulfanyl)]anilino-6,7-diethoxy-3-quinolinecarbonitrile (3) was identified as a MEK1 kinase inhibitor with exceptional activity against LoVo cells. The structure-activity relationships of the C-4 aniline substituents were explored, and water-solubilizing groups were added at the C-7 position to improve physical properties. Secondary cellular assays revealed that a compound possessing the appropriate aniline substituents inhibited MEK1 as well as MAPK phosphorylation, thereby acting as a dual inhibitor of the Ras-MAPK signaling cascade.
Bioorganic & Medicinal Chemistry | 2009
Yanong D. Wang; Erick Honores; Biqi Wu; Steve Johnson; Dennis Powell; Miriam Miranda; John P. McGinnis; Carolyn Discafani; Sridhar K. Rabindran; Wendy Cheng; Girija Krishnamurthy
Checkpoint deficiency of malignant cells can be exploited in cancer drug discovery. Compounds that selectively kill checkpoint-deficient cells versus checkpoint-proficient cells can be utilized to preferentially target tumor cells, while sparing normal cells. The protein p21(Wafl/Cipl/Sdi1) (hereafter referred to as p21) inhibits progression of the cell cycle by inhibiting the activity of G1 kinases (cyclin D/cdk4 and cyclin E-cdk2) and the G2 kinase (cyclin B/cdkl) in response to DNA damage or abnormal DNA content. The expression of p21 is often low in human cancer cells due to frequent loss of the upstream activator, p53, and is associated with poor prognosis in some cancer patients. Using an isogenic pair of cell lines, HCT116 (p21+/+) and 80S14 (p21-/-), we have disclosed previously a novel series of pyrazolo[1,5-a]pyrimidines that preferentially kill the p21-deficient cells. We will present the synthesis, biological activities and SAR study of a series of pyrazolo[1,5-a]pyrimidines with an optimized phenyl amide moiety at the C-7 position. The mechanism of action of these compounds will also be discussed.